Literature DB >> 23665218

p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Liz J Valente1, Daniel H D Gray, Ewa M Michalak, Josefina Pinon-Hofbauer, Alex Egle, Clare L Scott, Ana Janic, Andreas Strasser.   

Abstract

Activation of apoptosis through transcriptional induction of Puma and Noxa has long been considered to constitute the critical (if not sole) process by which p53 suppresses tumor development, although G1/S boundary cell-cycle arrest via induction of the CDK inhibitor p21 has also been thought to contribute. Recent analyses of mice bearing mutations that impair p53-mediated induction of select target genes have indicated that activation of apoptosis and G1/S cell-cycle arrest may, in fact, be dispensable for p53-mediated tumor suppression. However, the expression of Puma, Noxa, and p21 was not abrogated in these mutants, only reduced; therefore, the possibility that the reduced levels of these critical effectors of p53-mediated apoptosis and G1/S-cell-cycle arrest sufficed to prevent tumorigenesis could not be excluded. To resolve this important issue, we have generated mice deficient for p21, Puma, and Noxa (p21-/-puma-/-noxa-/- mice). Cells from these mice were deficient in their ability to undergo p53-mediated apoptosis, G1/S cell-cycle arrest, and senescence. Nonetheless, these animals remained tumor free until at least 500 days, in contrast to p53-deficient mice, which had all succumbed to lymphoma or sarcoma by 250 days. Interestingly, DNA lesions induced by γ-irradiation persisted longer in p53-deficient cells compared to wild-type or p21-/-puma-/-noxa-/- cells, and the former failed to transcriptionally activate several p53 target genes implicated in DNA repair. These results demonstrate beyond a doubt that the induction of apoptosis, cell-cycle arrest, and possibly senescence is dispensable for p53-mediated suppression of spontaneous tumor development and indicate that coordination of genomic stability and possibly other processes, such as metabolic adaptation, may instead be critical.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665218     DOI: 10.1016/j.celrep.2013.04.012

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  140 in total

Review 1.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

2.  The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development.

Authors:  Cassandra J Adams; Jennifer S Yu; Jian-Hua Mao; Kuang-Yu Jen; Sylvain V Costes; Mark Wade; Jocelyn Shoemake; Olulanu H Aina; Reyno Del Rosario; Phuong Thuy Menchavez; Robert D Cardiff; Geoffrey M Wahl; Allan Balmain
Journal:  Mol Carcinog       Date:  2015-08-27       Impact factor: 4.784

3.  Understanding the non-canonical pathways involved in p53-mediated tumor suppression.

Authors:  Kayla M Hager; Wei Gu
Journal:  Carcinogenesis       Date:  2013-12-31       Impact factor: 4.944

4.  Cancer: A piece of the p53 puzzle.

Authors:  Kathryn T Bieging; Laura D Attardi
Journal:  Nature       Date:  2015-03-18       Impact factor: 49.962

Review 5.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

6.  Tumor suppression by p53 involves inhibiting an enabler, FGF13.

Authors:  James J Manfredi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-12       Impact factor: 11.205

Review 7.  How do I kill thee? Let me count the ways: p53 regulates PARP-1 dependent necrosis.

Authors:  Rana Elkholi; Jerry E Chipuk
Journal:  Bioessays       Date:  2013-10-24       Impact factor: 4.345

8.  p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.

Authors:  Phillippe P Gonzalez; Jungeun Kim; Rui Pedro Galvao; Nichola Cruickshanks; Roger Abounader; Hui Zong
Journal:  Glia       Date:  2018-02-02       Impact factor: 7.452

9.  Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses.

Authors:  Yang Ou; Shang-Jui Wang; Dawei Li; Bo Chu; Wei Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

10.  Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.

Authors:  Beng Hooi Phang; Rashidah Othman; Gaelle Bougeard; Ren Hui Chia; Thierry Frebourg; Choong Leong Tang; Peh Yean Cheah; Kanaga Sabapathy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.